| Literature DB >> 33083329 |
Soheila Shaghaghian1, Behrooz Astaneh1.
Abstract
BACKGROUND: Although much medical knowledge comes from observational research, such studies are more prone to confounding and bias than others. This study was conducted to evaluate the adherence of the observational studies published in Iranian medical journals to the STROBE (strengthening the reporting of observational studies in epidemiology) statement.Entities:
Keywords: Iran; Journal; Observational study; Quality; Strengthening the reporting of observational studies in epidemiology (STROBE)
Year: 2020 PMID: 33083329 PMCID: PMC7554393 DOI: 10.18502/ijph.v49i8.3896
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Fig. 1:Flow chart shows how the journals and articles were selected
Characteristics of the studied articles and their effect on the adherence of the articles to the STROBE statement (N=150)
| Language | |||||
| -English | 100 (66.7) | 49±9 | 0.018 | − 0.004 | 0.834 |
| -Persian | 50 (33.3) | 45±9 | - | - | |
| Indexed in | |||||
| -PubMed/ISI | 50 (33.3) | 52±8 | <0.001 | 0.072 | <0.001 |
| -Other databases | 100 (66.7) | 45±9 | - | - | |
| Publication year | |||||
| -2015 | 13 (8.7) | 42±7a | 0.028 | − 0.043 | − 0.098 |
| -2016 | 105 (70.0) | 49±9b | 0.042 | 0.149 | |
| -2017 | 32 (21.3) | 46±10ab | |||
| Authors’ affiliation | |||||
| -Iran | 119 (79.3) | 47±9 | 0.061 | -− 0.069 | − 0.044 |
| -Iran & other countries | 7 (4.7) | 54±11 | |||
| -No Iran | 24 (16.0) | 50±9 | <0.001 | 0.966 | |
ISI: Institute of scientific information // N: Number // SD: Standard Deviation
Independent sample T- test //
One Way ANOVA
Different letters show statistically significant differences.
Adherence of the articles published in Iranian medical journals to the STROBE statement (N=150)
| Title & abstract | Indicate the study’s design in the title or the abstract | 88 (58.7) | 2 (1.3) | 60 (40.0) | 0 (0.0) |
| An informative and balanced abstract | 67 (44.7) | 82 (54.7) | 1 (0.7) | 0 (0.0) | |
| Introduction | Explain the scientific background of the investigation | 118 (78.7) | 28 (18.7) | 4 (2.7) | 0 (0.0) |
| Explain the rationale for the investigation being reported | 92 (61.3) | 51 (34.0) | 7 (4.7) | 0 (0.0) | |
| State the goal of the study | 114 (76.0) | 30 (20.0) | 6 (4.0) | 0 (0.0) | |
| State specific objectives or pre-specified hypotheses | 19 (12.7) | 12 (8.0) | 112 (74.7) | 7 (4.7) | |
| Methods | |||||
| Present study design early in the paper | 92 (61.3) | 1 (0.7) | 57 (38.0) | 0 (0.0) | |
| Describe the setting and locations of the study | 124 (82.7) | 8 (5.3) | 18 (12.0) | 0 (0.0) | |
| Describe the period of recruitment and data collection | 94 (62.7) | 3 (2.0) | 53 (35.3) | 0 (0.0) | |
| Describe the period of exposure | 9 (6.0) | 1 (0.7) | 6 (4.0) | 134 (89.3) | |
| Describe the period of follow-up | 8 (5.3) | 0 (0.0) | 4 (2.7) | 138 (92.0) | |
| Give the Inclusion criteria of participants | 104 (69.3) | 13 (8.7) | 33 (22.0) | 0 (0.0) | |
| Give the source population of participants | 127 (84.7) | 11 (7.3) | 12 (8.0) | 0 (0.0) | |
| Give methods of selection of participants (sampling) | 86 (57.3) | 20 (13.3) | 44 (29.3) | 0 (0.0) | |
| Give methods of follow-up (only for cohort studies, N=5) | 1 (20.0) | 0 (0.0) | 2 (40.0) | 2 (40.0) | |
| Give the rationale for the choice of cases and controls (for case-control studies, N=21) | 3 (14.3) | 1 (4.8) | 13 (61.9) | 4 (19.0) | |
| For matched studies, give matching criteria (for cohort and case-control studies, N=26) | 7 (26.9) | 1 (3.8) | 2 (7.7) | 16 (61.6) | |
| For matched studies, give number of controls per case (for case-control studies, N=21) | 4 (19.0) | 0 (0.0) | 6 (28.6) | 11 (52.4) | |
| For matched studies, give number of exposed and unexposed (for cohort studies, N=5) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 4 (80.0) | |
| Define all outcomes | 124 (82.7) | 12 (8.0) | 13 (8.7) | 1 (0.7) | |
| Define all exposures | 88 (58.7) | 20 (13.3) | 31 (20.7) | 11 (7.3) | |
| Define all potential confounders | 31 (20.7) | 9 (6.0) | 99 (66.0) | 11 (7.3) | |
| Define all effect modifiers | 0 (0.0) | 0 (0.0) | 143 (95.3) | 7 (4.7) | |
| Give methods of measurement | 118 (78.7) | 17 (11.3) | 15 (10.0) | 0 (0.0) | |
| Give sources of data for methods of measurement | 86 (57.3) | 16 (10.7) | 43 (28.7) | 5 (3.3) | |
| Describe comparability of measurement methods between two groups | 7 (4.7) | 1 (0.7) | 28 (18.7) | 114 (76.0) | |
| Describe any efforts to address potential sources of bias | - | - | - | - | |
| Report of sample size calculations | 31 (20.7) | 5 (3.3) | 113 (75.3) | 1 (0.7) | |
| Description about groupings chosen for quantitative variables | 49 (32.7) | 2 (1.3) | 29 (19.3) | 70 (46.7) | |
| Description about why the groupings chosen for quantitative variables | 24 (16.0) | 4 (2.7) | 50 (33.3) | 72 (48.0) | |
| Description of unadjusted statistical methods | 132 (88.0) | 0 (0.0) | 9 (6.0) | 9 (6.0) | |
| Description of the statistical methods used to control for confounding | 62 (41.3) | 0 (0.0) | 79 (52.7) | 9 (6.0) | |
| Description of statistical methods used to examine subgroups and interactions | 0 (0.0) | 0 (0.0) | 143 (95.3) | 7 (4.7) | |
| Description of how missing data were addressed | 0 (0.0) | 0 (0.0) | 150 (100.0) | 0 (0.0) | |
| Explanation about how loss to follow-up was addressed (cohort studies, N=5) | 0 (0.0) | 0 (0.0) | 5 (100.0) | 0 (0.0) | |
| Explanation about how matching of cases and controls was addressed (only case-control studies, N=21) | 0 (0.0) | 0 (0.0) | 11 (52.4) | 10 (47.6) | |
| Describe analytical methods taking account of sampling strategy (cross sectional studies, N=124) | 0 (0.0) | 0 (0.0) | 123 (99.2) | 1 (0.8) | |
| Description about any sensitivity analyses | 1 (0.7) | 0 (0.0) | 148 (98.7) | 1 (0.7) | |
| Results | |||||
| Report numbers of individuals eligible for the study | 10 (6.7) | 1 (0.7) | 139 (92.7) | 0 (0.0) | |
| Report numbers of individuals included in the study | 89 (59.3) | 0 (0.0) | 61 (40.7) | 0 (0.0) | |
| Give reasons for non-participation at each stage | 4 (2.7) | 5 (3.3) | 140 (93.3) | 1 (0.7) | |
| Use of a flow diagram for showing participants | 0 (0.0) | 0 (0.0) | 149 (99.3) | 1 (0.7) | |
| Give characteristics of study participants | 103 (68.7) | 19 (12.7) | 28 (18.7) | 0 (0.0) | |
| Give information on exposures | 105 (70.0) | 16 (10.7) | 19 (12.7) | 10 (6.7) | |
| Give information on potential confounders | 41 (27.3) | 7 (4.7) | 93 (62.0) | 9 (6.0) | |
| Indicate number of participants with missing data for each variable of interest | 8 (5.3) | 1 (0.7) | 141 (94.0) | 0 (0.0) | |
| Summarize follow-up time (only for cohort studies, N=5) | 3 (60.0) | 0 (0.0) | 2 (40.0) | 0 (0.0) | |
| Report numbers of outcome events or summary measures over time (only cohort studies, N=5) | 5 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Report numbers in each exposure category (only case-control studies, N=21) | 18 (85.7) | 2 (9.5) | 1 (4.8) | 0 (0.0) | |
| Report numbers of outcome events or summary measures (only cross sectional studies, N=124) | 109 (87.9) | 2 (1.6) | 12 (9.7) | 1 (0.8) | |
| Give unadjusted estimates and their precision | 125 (83.3) | 13 (8.7) | 1 (0.7) | 11 (7.3) | |
| Give confounder-adjusted estimates and their precision | 56 (37.3) | 3 (2.0) | 82 (54.7) | 9 (6.0) | |
| Make clear which confounders were adjusted for | 48 (32.0) | 2 (1.3) | 91 (60.7) | 9 (6.0) | |
| Make clear why the confounders were included | 5 (3.3) | 0 (0.0) | 136 (90.7) | 9 (6.0) | |
| Report category boundaries when continuous variables were categorized | 46 (30.7) | 9 (6.0) | 26 (17.3) | 69(46.0) | |
| Consider translating estimates of relative risk into absolute risk | 0 (0.0) | 0 (0.0) | 0 (0.0) | 150 (100) | |
| Report analyses of subgroups and interaction | 1 (0.7) | 1 (0.7) | 141 (94.0) | 7 (4.7) | |
| Report sensitivity analyses | 2 (1.3) | 0 (0.0) | 148 (98.7) | 0 (0.0) | |
| Discussion | |||||
| Summarize key results in the beginning of discussion | 66 (44.0) | 23 (15.3) | 61 (40.7) | 0 (0.0) | |
| Discuss limitations of the study | 81 (54.0) | 9 (6.0) | 60 (40.0) | 0 (0.0) | |
| Give interpretation of results considering results from similar studies, and other relevant evidence | 132 (88.0) | 13 (8.7) | 5 (3.3) | 0 (0.0) | |
| Discuss the generalizability (external validity) of the study | 5 (3.3) | 0 (0.0) | 145 (96.7) | 0 (0.0) | |
| Other information | |||||
| Give the source of funding | 81 (54.0) | 7 (4.7) | 62 (41.3) | 0 (0.0) | |
Fig. 2:The adherence of sections of articles published in Iranian Medical journals to the STROBE statement